Active Ingredient History
Rifaximin is a structural analog of rifampin and a non-systemic, gastrointestinal site-specific antibiotic. Rifaximin acts by inhibiting bacterial ribonucleic acid (RNA) synthesis and contributes to restore intestinal microflora imbalance. It is FDA approved for the treatment of travelers’ diarrhea, reduction in risk of overt hepatic encephalopathy (HE) recurrence and treatment of irritable bowel syndrome with diarrhea. More common side effects are: black, tarry stools; dizziness or lightheadedness; muscle spasm; rapid breathing; shortness of breath; trouble sleeping. Co-administration of cyclosporine, with XIFAXAN resulted in 83-fold and 124-fold increases in rifaximin mean Cmax in healthy subjects. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hepatic Encephalopathy (approved 2004)
Irritable Bowel Syndrome (approved 2004)
Abdominal Pain (Phase 2/Phase 3)
Acute-On-Chronic Liver Failure (Early Phase 1)
Alzheimer Disease (Phase 2)
Anemia, Sickle Cell (Phase 2)
Anti-Bacterial Agents (Phase 2)
Ascites (Phase 4)
Bacterial Infections (Phase 3)
Bone Marrow Transplantation (Phase 1)
Breast Neoplasms (Phase 2)
Cholangitis (Phase 1)
Clostridium Infections (Phase 4)
Colitis, Collagenous (Phase 3)
Colitis, Microscopic (Phase 2)
Constipation (Phase 3)
Crohn Disease (Phase 3)
Cystic Fibrosis (Phase 2/Phase 3)
Diabetes Mellitus (Phase 2)
Diarrhea ()
Diverticular Diseases (Phase 4)
Diverticulitis (Phase 2/Phase 3)
Dysbiosis (Phase 4)
Dyspepsia (Phase 2/Phase 3)
Escherichia coli Infections (Phase 2)
Fear (Phase 2/Phase 3)
Fibrosis (Phase 4)
Gastrointestinal Microbiome (Phase 4)
Healthy Volunteers (Phase 2/Phase 3)
Heart Failure, Systolic (Phase 2)
Hepatic Encephalopathy (Phase 4)
Hepatitis, Alcoholic (Phase 3)
Hepatitis B (Early Phase 1)
Hepatitis C (Phase 4)
HIV (Phase 4)
HIV Infections (Phase 2)
Hypersensitivity (Phase 2)
Hypertension, Portal (Phase 4)
Immunoglobulin Light Chains (Phase 1)
Infections (Phase 2)
Inflammation (Phase 1/Phase 2)
Insulin Resistance (Phase 2)
Intestinal Diseases (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 4)
Irritable Bowel Syndrome (Phase 4)
Kidney Failure, Chronic (Early Phase 1)
Leukemia, Myeloid, Acute (Phase 2)
Liver Cirrhosis (Phase 4)
Liver Diseases (Phase 4)
Metabolic Syndrome (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity (Phase 2)
Paraproteinemias (Phase 1)
Parkinson Disease (Phase 3)
Pathologic Processes (Phase 4)
Peritonitis (Phase 3)
Persian Gulf Syndrome (Phase 1)
Pharmacokinetics (Phase 1)
Primary Immunodeficiency Diseases (Phase 4)
Psychological Distress (Phase 2/Phase 3)
Rectal Neoplasms (Phase 3)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Rifaximin (Phase 2/Phase 3)
Rosacea (Phase 2)
Vaginosis, Bacterial (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)
Weight Loss (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
